MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital

The eighth edition of Med x Tech Summit Asia (MedTex 2025), co-organized by the Institute for Biotechnology and Medicine Industry (IBMI), the Research Center for Biotechnology and Medicine Policy (RBMP) and Everbright Biofund, was grandly held in Taipei on December 3. The forum brings together leading venture capital firms from Europe, the United States and Israel along with ten portfolio companies. IBMI President Chi-Huey Wong emphasized Taiwan’s strengths in semiconductor technologies, biomedical expertise and engineering talent, calling MedTex a strategic bridge to introduce global technologies and capital into Taiwan while showcasing local innovation to the world. 

As one of the board members of the Everbright Biofund, IMBI Vice President Pan-Chyr Yang noted that Everbright Biofund has invested in several portfolio companies in Taiwan, including Syncell (optical-targeting protein-capture instruments), ImmunAdd (synthetic saponin vaccine adjuvants), and StemCyte (umbilical cord-blood cell therapy), demonstrating Taiwan’s strong R&D base and its capacity to contribute meaningfully to global biomedical innovation.

Investor Playbooks for AI-enabled Life Sciences

The two keynotes delivered the investment frame that investors will use throughout 2026. Noel Jee of Novo Holdings framed the investment backdrop with a data-driven view of recent biotech M&A and capital cycles. He noted a structural shift toward a larger number of smaller deals since 2008 and argued that long-term, life-science-focused investors should prioritize durable, science-backed platforms that demonstrably reduce clinical or development risk. Jee flagged macro tailwinds for 2026, including an easing of interest rates that could lower the cost of capital for biotechs, and he highlighted a shortening interval between company founding and private financing as evidence that quality scientific teams are attracting earlier institutional support.

Yaron Daniely of Israel’s aMoon Fund followed with a practitioner’s framework for sorting high-potential healthtech opportunities. Daniely distilled four focus areas of healthcare innovation: prevention and early diagnosis; improving treatment quality and outcomes; reducing caregiver burden by automating non-clinical tasks; and lowering overall system costs. He pressed founders to pair AI modelling with defensible datasets and clinical hypotheses that map to payer-relevant endpoints. 

Global VCs See 2026 as a Pivotal Year for Clinical-Stage Biotech

A fireside chat featuring investors from Insight Partners, Playground Global, Illumina Ventures and Ascenta Capital explored how market conditions, scientific progress and global capital flows are shaping what many view as a pivotal year ahead for healthcare and biotech ventures. The discussion, moderated by Aiden Aceves, centered on a cautiously optimistic outlook for 2026, driven by signs of recovery in U.S. capital markets, easing inflation and an unusually strong cohort of clinical-stage programs expected to deliver meaningful data. Panelist Leighanne Oh noted that clinical proof-of-concept has become the defining factor for investment decisions, with capital moving toward companies capable of showing real patient-level outcomes and away from early projects still years from validation.

The venture capitalists also addressed how the industry is rethinking the role of platform technologies. While enthusiasm for “platform companies” has cooled in recent years, the panel emphasized that platforms remain compelling when they demonstrate repeatable success, meaning they generate multiple drug candidates rather than a single promising asset. Oh described an informal benchmark across the industry: one successful program de-risks the concept, two show the results were not luck, and the third establishes the platform as a genuine engine for drug creation. Nate Chang added that modern platforms increasingly combine biology, engineering and AI to shorten preclinical timelines, while Charles Lin emphasized that strong clinical assets still anchor valuation even as platforms create flexibility, allowing biotech companies to develop backups or structure diversified partnerships with pharma.

Finally, the conversation turned toward financing trends and the shifting geography of capital. With U.S. research budgets tightening and tariffs altering supply chains, investors are tapping alternative funding models such as royalty financing, structured credit and government-matched programs—most notably in Japan, where start-ups can double private investment through public support. Both Chang and Lin noted that these conditions are driving more collaboration across Asia, where Taiwan, Singapore, Japan and Korea are increasingly seen as strategic hubs for innovation and manufacturing. Across all themes, Aceves underscored what ultimately shapes long-term success: founders who are able to communicate clearly, build complete leadership teams, understand their financing milestones, and align their investors around realistic, data-driven plans.

AI Drug Discovery & Therapeutics: Tech Platforms Meet Translational Rigor

The first pitch session of the event brought together four AI-powered drug discovery teams whose platforms span protein structure prediction and engineering, in vivo screening of protein candidates, infectious-disease treatment, and peptide therapeutics. Manifold Bio presented a highly differentiated in-vivo biologics discovery engine built to identify tissue-targeted protein therapeutics at scale, enabling precise optimization of delivery to “hard-to-reach” organs such as the brain. A major validation of this platform came in early November, when the Harvard spinout announced a US$2 billion strategic collaboration with Roche to develop multiple next-generation brain shuttles for neurological diseases. 

As one of the portfolio companies of the Everbright Biofund, Iambic Therapeutics presented its AI-augmented small-molecule discovery pipeline and highlighted IAM1363, an AI-designed HER2 inhibitor characterized by reported pan-mutant activity and brain penetration, illustrating how model-driven chemistry can produce candidates with differentiated target selectivity and CNS exposure. ArrePath positioned itself in the anti-infective space, using computational mapping to identify previously under-exploited bacterial vulnerabilities and translate those findings into novel small-molecule antibiotic programs. 

Myria Biosciences explained its “synthetic intelligence” approach that combines AI, synthetic biology, and ultra-high-throughput cellular production and screening to generate and evaluate millions of novel, nature-inspired small molecules and peptides in weeks rather than months.

Medical Robotics & New Therapeutics: Hardware, Workflow and Clinical Impact

The second session emphasized engineered systems and programmable biology. Nanoflex Robotics presented a telerobotic endovascular platform that integrates ultra-flexible robotic instruments with advanced navigation to enable remote or assisted thrombectomy and vascular interventions. caVos Biotherapeutics described a multi-layer computational genomics engine that mines comparative evolutionary biology to discover naturally occurring resistance and anti-cancer mechanisms, which the Israeli company translates into RNA-based and other therapeutic modalities in preclinical programs. 

Strand Therapeutics focused on programmable mRNA and synthetic-biology constructs engineered to modulate immune responses in cancer and severe disease settings. Their platform centers on controllable expression programs that can tune potency, timing, and tissue selectivity of biologics.

Healthcare & Drug Innovation: Modality Innovation Addressing Difficult Targets

The final pitch session concentrated on modality innovation and translational modalities that aim to address historically difficult targets. Coltac Therapeutics presented a molecular-glue approach intended to induce selective protein degradation for targets considered undruggable by traditional inhibitors, leveraging chemistry that enforces proximity between an E3 ligase and target proteins. 

Infinimmune outlined immune-modulatory programs that combine patient-centric biology with tumor-directed strategies, integrating biomarker frameworks to stratify patients and accelerate readouts of immune engagement. Insamo showcased an orally bioavailable cyclic-peptide platform engineered for cell penetration, giving access to intracellular targets that are typically inaccessible to large biologics. 

From Innovation Showcase to Global Deal Flow

MedTex 2025 concludes with strong signals of Taiwan’s intent to elevate its role in the global biotech value chain. Everbright Biofund presented its active investments in four frontier technology companies, demonstrating early outcomes of cross-border collaboration. Organizers reaffirmed that MedTex will continue serving as a long-term channel connecting global capital with breakthrough healthcare technologies, enabling AI-empowered science in Taiwan to reach broader markets.

Furthermore, given Taiwan’s world-class healthcare system, featuring smart hospitals and medical centers with international recognition, MedTex serves as an exciting platform for cross-border healthcare and medtech collaborations, making Taiwan an excellent venue for clinical adoption of biotech and medical innovations from around the globe.

Related posts:

Med X Tech Summit Asia (MEDTEX) 2018 – Overview of Day 1 Program How Can Taiwan’s Biopharma Seize the Next Global Business Opportunity? – An Interview with Dr. Jerome Shen Taiwan’s Semiconductor Industry Steers Global Tech Amidst Economic Headwinds and Regionalization Asia Microbiome Conference Reached a New Milestone: From Innovative Forum to Microbiome Carnival

Author

Richard Chau